Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Nuvation Bio Inc.

    NYSE: NUVB · Real-Time Price · USD
    1.85
    0.12 (6.94%)
    At close: Jun 16, 2025, 3:59 PM
    1.87
    1.08%
    After-hours: Jun 16, 2025, 07:58 PM EDT
    6.94%
    Bid 1.86
    Market Cap 627.64M
    Revenue (ttm) 10.96M
    Net Income (ttm) -606.38M
    EPS (ttm) -2.2
    PE Ratio (ttm) -0.84
    Forward PE -2.87
    Analyst Buy
    Ask 1.89
    Volume 9,182,498
    Avg. Volume (20D) 4,259,539
    Open 1.68
    Previous Close 1.73
    Day's Range 1.57 - 1.89
    52-Week Range 1.54 - 3.97
    Beta 1.37

    About NUVB

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol NUVB
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for NUVB stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    5 months ago
    +14.44%
    Nuvation Bio shares are trading higher after RBC C... Unlock content with Pro Subscription
    10 months ago
    -5.36%
    Nuvation Bio shares are trading lower. The company reported Q2 financial results.
    news image

    6 days ago · reuters.com

    US FDA approves Nuvation Bio's lung cancer therapy

    The U.S. Food and Drug Administration said on Wednesday it has approved Nuvation Bio's therapy for patients with a type of lung cancer.

    news image

    6 days ago · businesswire.com

    U.S. Food and Drug Administration Approves Nuvation Bio's IBTROZI™ (taletrectinib), a Next-Generation Oral Treatment for Advanced ROS1-Positive Non-Small Cell Lung Cancer

    NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that the U.S. Food and Dru...

    news image

    6 days ago · https://www.defenseworld.net

    UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $925,000 Holdings in Nuvation Bio Inc. (NYSE:NUVB)

    UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in Nuvation Bio Inc. (NYSE:NUVB – Free Report) by 54.2% in the 4th quarter, according to the company in i...

    news image

    3 weeks ago · businesswire.com

    Nuvation Bio To Present New Data from Pivotal Clinical Studies of Taletrectinib in Advanced ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2025 Annual Meeting

    NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that additional results fr...

    news image

    1 month ago · businesswire.com

    Nuvation Bio to Present Matching-adjusted Indirect Comparison Data for Taletrectinib vs. Entrectinib at ISPOR 2025

    NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that new data from a match...

    news image

    1 month ago · seekingalpha.com

    Nuvation Bio Inc. (NUVB) Q1 2025 Earnings Call Transcript

    Nuvation Bio Inc. (NYSE:NUVB ) Q1 2025 Earnings Call May 7, 2025 4:30 PM ET Company Participants J.R. DeVita - Investor Relations David Hung - Founder, President and Chief Executive Officer Colleen Sj...

    news image

    1 month ago · zacks.com

    Nuvation Bio Inc. (NUVB) Reports Q1 Loss, Tops Revenue Estimates

    Nuvation Bio Inc. (NUVB) came out with a quarterly loss of $0.16 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.07 per share a year ago.

    news image

    1 month ago · seekingalpha.com

    Nuvation Bio: A Real Shot To Move The Needle In Lung Cancer Subtypes

    Nuvation Bio's taletrectinib shows strong efficacy in ROS1-positive NSCLC, with a 90.1% response rate, and FDA approval is likely by June 2025. Financially robust, Nuvation Bio has over three years of...

    news image

    1 month ago · businesswire.com

    Nuvation Bio to Present at The Citizens Life Sciences Conference

    NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company tackling some of the toughest challenges in cancer treatment, today announced that Philippe Sauvage, Chief Financia...

    news image

    1 month ago · businesswire.com

    Nuvation Bio to Report Results for First Quarter 2025 and Provide Business Update on May 7, 2025

    NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on solving some of the toughest challenges in cancer treatment, will announce results for the first quarter...

    Add to Watchlist